Addressing Our Nation’s Toxic School Infrastructure in the Wake of COVID-19

The commentary argues that we need to address the wide variance in school building quality under and after COVID-19. Evidence suggests that historical underinvestment in school facility capital and maintenance has created unhealthy school buildings across the nation. Federal funding and research is necessary to ensure that schools are healthy places for educators, families, and youth even after the pandemic ends.

Gender Representation Cues Labels of Hard and Soft Sciences

While women's representation in STEM fields has increased over the past several decades, some fields have seen a greater increase women's participation than others. In the present research, we explore how women's participation in STEM disciplines influences labeling of those disciplines as hard vs. soft sciences. Study 1 found that increasing perceived participation of women in a STEM discipline increased the likelihood that participants would label it a soft science. Study 2 found that among people who did not work in science, this tendency to associate women's participation with soft science was correlated with endorsement of stereotypes about women's STEM competency. And Studies 3A and 3B showed that labeling disciplines as soft sciences led to the fields being devalued, deemed less rigorous, and less worthy of federal funding. These studies show that stereotypes about women's STEM competency can impact perceptions of fields in which women participate, with consequences for how scientific disciplines are perceived.

Pharmaceutical policies for diseases related to poverty in Brazil: a review

The "epidemiological transition" has fostered increasing attention to chronic and non-communicable diseases, but neglected diseases are still present and their relationship with the population's socioeconomic inequalities is increasingly evident, so much so that there has been a conceptual conversion to call them “poverty-related diseases”. It is a necessary to review and to discuss the characteristics and challenges of Brazilian pharmaceutical policies for populations affected by diseases related to poverty. This review of the literature was carried out, with works of the last 10 years dealing with the theme and the Brazilian reality. Out of the 272 identified articles, only 43 publications were included in this study. The results were: (i) the difficulties of investing in the research, development and production of new drugs for these diseases; (ii) the characteristics of access policies to medicines already available, their advances and limitations; (iii) and issues related to the right to comprehensive pharmaceutical assistance. Therefore, for the available therapies, national production and federal funding contributed to guarantee the supply. Assisted qualification actions are necessary and little discussed in area studies.

Conceptualizing and Measuring the Promotion of Nonprofit Organizations’ Evidence Use by U.S. Social Service Funding Programs

Previous research on U.S. federal promotion of evidence-based programming has focused on evidence-based program registries and concludes their usefulness is undermined by prioritizing internal validity over external validity. This research explores how federal funding programs are actually promoting funded nonprofit organizations’ evidence use instead of what we might infer from registries alone. An inductively developed conceptual framework is applied to describe all 53 fiscal year (FY) 2019 social service funding programs that include nonprofit organizations among the eligible applicants, finding they promote multiple types of evidence use, with generally low coerciveness, and with applicants frequently co-determining what counts as evidence. These findings point to promotion of evidence use that balances evidence-driven prescriptiveness and enabling nonprofits’ innovation.

Information Opacity in Biopharmaceutical Innovation Through the Lens of COVID-19

The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.